Results 181 to 190 of about 69,107 (331)

Dipeptidyl Peptidase 4 Restoration Facilitates Antitumor Immunity in KRAS-LKB1-Mutant Lung Cancer. [PDF]

Cancer Res Commun
Tenma T, Yoshida R, Yanada H, Nitanai K, Nagato T, Oyama K, Sasaki N, Homme M, Mori C, Ohkuri T, Ono Y, Tange S, Minami Y, Kobayashi H, Mizukami Y, Barbie DA, Kitajima S, Sasaki T.   +17 more
europepmc   +1 more source

Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium‐glucose co‐transporter‐2 inhibitors with those receiving dipeptidyl peptidase‐4 inhibitors, using a supervised machine‐learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database

, 2019
Fang Liz Zhou, Hirotaka Watada, Yuki Tajima, Mathilde Berthelot, Dian Kang, C. Esnault, Yujin Shuto, Hiroshi Maegawa, Daisuke Koya   +8 more
openalex   +1 more source

Dapagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in people with type 2 diabetes ( CVD‐REAL Nordic ) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study [PDF]

, 2017
Frederik Persson, Thomas Nyström, Marit E. Jørgensen, Bendix Carstensen, Hanne L. Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Jan W. Eriksson, Anna Norhammar, Johan Bodegård, Kåre I. Birkeland   +11 more
openalex   +1 more source

ERRATUM: Effects of dipeptidyl peptidase-4 inhibitor in insulin-resistant rats with myocardial infarction. [PDF]

J Endocrinol
Apaijai N, Inthachai T, Lekawanvijit S, Chattipakorn SC, Chattipakorn N.   +4 more
europepmc   +1 more source

QSAR rationales for the dipeptidyl peptidase-4 (DPP-4) inhibitors: The imidazolopyrimidine amides

, 2020
Raghuraj Parihar, Sharma Brij Kishore
openalex   +1 more source

Sodium–glucose cotransporter 2 inhibitors for hypertension in cardiovascular–kidney–metabolic syndrome

Experimental Physiology, EarlyView.
Abstract The antihypertensive mechanism of sodium–glucose cotransporter 2 (SGLT2) inhibitors has been traditionally attributed to osmotic diuresis. However, emerging evidence reveals multifaceted mechanisms beyond diuresis, including regulation of the renin–angiotensin–aldosterone system, sympathetic nervous system suppression, ion homeostasis ...
Chunxiang Xu, Xingyu Qiu, Nan Xu, Gensheng Zhang, Enyin Lai, Liang Zhao   +5 more
wiley   +1 more source

Dipeptidyl Peptidase 4 Inhibitors: Novel Therapeutic Agents in the Management of Type II Diabetes Mellitus. [PDF]

Pharmacoepidemiol Drug Saf
Aloke C, Adelusi OA, Onisuru OO, Iwuchukwu EA, Achilonu I.   +4 more
europepmc   +1 more source

Dipeptidyl Peptidase-4 Inhibitor Increases Vascular Leakage in Retina through VE-cadherin Phosphorylation [PDF]

, 2016
Choon-Soo Lee, Yun Gi Kim, Hyun‐Jai Cho, Jonghanne Park, Heewon Jeong, Sang‐Eun Lee, Seung‐Pyo Lee, Hyun‐Jae Kang, Hyo‐Soo Kim   +8 more
openalex   +1 more source

Targeting Tumor Dormancy and Recurrence: Molecular Mechanisms and Peptide Therapeutic Delivery

MedComm – Oncology, Volume 5, Issue 1, March 2026.
This review summarizes the molecular mechanisms that regulate tumor dormancy and its role in cancer recurrence, with emphasis on immune evasion, extracellular matrix remodeling, metabolic regulation and angiogenic switching. It further discusses emerging peptide–based therapeutic strategies aimed at detecting, modulating, and eliminating dormant tumor ...
Abdur Raheem Aleem, Atif Ali, Wajid Ali, Yuying Cheng, Zhibin Yan, Chaoyi Xia, Chenguang Liu, Caiyun Fu, Yiren Hu, Xi Wang   +9 more
wiley   +1 more source

Case report: Epidermolysis bullosa acquisita following dipeptidyl peptidase-4 inhibitor therapy and complicated by immune thrombocytopenic purpura. [PDF]

Front Immunol
Kawamoto H, Sasaki N, Ueda Y, Ishii N, Sawada Y.   +4 more
europepmc   +1 more source